New treatment to improve blood flow after heart procedures
Official title: Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
Funded at Apt Therapeutics, INC. · NIH-11077205 · Data updated 2026-11-12
This study is testing a new treatment that helps improve blood flow and reduce complications for people who are getting heart procedures after a heart attack, aiming to keep them safe while protecting their heart.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Apt Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Naperville, UNITED STATES) |
| Project start | May 1, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,717,926 |
| NIH project number | 5R44HL169132-03 |
| Project ID | NIH-11077205 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients experiencing acute myocardial infarction who are scheduled for percutaneous coronary intervention.
✕Less likely to help
Patients with contraindications to antithrombotic therapy or those not undergoing PCI may not benefit from this research.
What this research studies
This research investigates a novel therapy designed to enhance blood flow and reduce complications in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. The approach combines a unique fusion protein that acts as an antiplatelet and anticoagulant agent, aiming to minimize the risk of bleeding while effectively protecting the heart's microcirculation. By addressing the limitations of current antithrombotic treatments, this therapy seeks to improve patient outcomes and reduce the incidence of heart failure following PCI. Patients may be monitored for their response to this innovative treatment during the study period.
Why it matters
Potential benefit: If successful, this research could lead to improved heart function and reduced complications for patients undergoing heart procedures.
How similar studies have gone: While there have been advancements in antithrombotic therapies, this specific approach using a novel fusion protein is considered innovative and has not been extensively tested in prior studies.
Where this research is happening
-
Apt Therapeutics, INC.
Naperville, United States Active
Researchers
- Principal investigator: Chen, Ridong — Apt Therapeutics, INC.
- Study coordinator: Chen, Ridong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.